Core Medical Publishing
Core Medical Publishing is a new independent publishing company that provides healthcare professionals with knowledge-based publications and educational programs that facilitate critical medical decision making. Core Medical Publishing produces Core Evidence, the first international peer-reviewed journal that rigorously evaluates the evidence for rational drug selection based on outcomes central to informed medical decision making, with the goal of improved quality of care. Each issue reviews drugs from phase I through postlaunch. Drugs are selected on the basis of their potential impact on outcomes and resource utilization.
[Read full details]

:::::::: Selected titles ::::::::

Tadalafil: the evidence for its clinical potential in the treatment of pulmonary arterial hypertension
Based on studies of sildenafil, a related phosphodiesterase type 5 inhibitor, and the findings of initial pilot studies, tadalafil appears to have excellent potential in pulmonary hypertension
[Read full details]

Eritoran: the evidence of its therapeutic potential in sepsis
Eritoran is an exciting potential therapeutic option for management of sepsis with a reasonable safety and tolerability profile that must be validated by rigorous randomized clinical trials.
[Read full details]

Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy
The current evidence shows that a fixed-dose formulation of pioglitazone and metformin offers an effective option with some advantages in the management of patients with type 2 diabetes.
[Read full details]

Abatacept: the evidence for its place in the treatment of rheumatoid arthritis
With its different mechanism of action, abatacept may be an alternative therapy for patients with an inadequate response to other arthritis therapies, especially for those patients with RA refractory to anti-TNF treatment.
[Read full details]

Rimonabant: the evidence for its use in the treatment of obesity and the metabolic syndrome
The evidence clearly supports the use of rimonabant 20 mg/day along with dietary modification to reduce cardiovascular risk in obese and overweight patients, including those with diabetes.
[Read full details]

Infliximab: the evidence for its place in therapy in ulcerative colitis
Infliximab has clearly been shown to induce clinical response and remission short term and long term, to induce and maintain mucosal healing, and to spare steroids in patients with moderate to severe ulcerative colitis.
[Read full details]

There are lots more publications available at www.ThePharmYard.com which is managed by NetworkPharma Ltd and provides
you with instant access to a unique database of specialist information relevant to the medical and pharmaceutical industries.
Titles from a diverse range of independent publishers are provided in electronic document format for immediate download and use.
We are keen to hear from authors and publishers of relevent information and from anyone interested in offering an affiliate service. Please contact us to find out more.